GQG Partners LLC Makes New Investment in CVS Health Corporation $CVS

by · The Markets Daily

GQG Partners LLC acquired a new stake in CVS Health Corporation (NYSE:CVS – Free Report) during the second quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 7,955,411 shares of the pharmacy operator’s stock, valued at approximately $822,989,000. CVS Health makes up 1.5% of GQG Partners LLC’s portfolio, making the stock its 21st largest holding. GQG Partners LLC owned 0.62% of CVS Health at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of the company. Elevation Wealth Partners LLC lifted its position in shares of CVS Health by 41.8% during the 2nd quarter. Elevation Wealth Partners LLC now owns 356 shares of the pharmacy operator’s stock worth $37,000 after purchasing an additional 105 shares during the last quarter. Apella Capital LLC increased its position in CVS Health by 1.7% in the 2nd quarter. Apella Capital LLC now owns 6,940 shares of the pharmacy operator’s stock worth $724,000 after buying an additional 117 shares during the period. CYBER HORNET ETFs LLC lifted its holdings in shares of CVS Health by 4.1% during the third quarter. CYBER HORNET ETFs LLC now owns 3,442 shares of the pharmacy operator’s stock worth $259,000 after buying an additional 134 shares during the last quarter. Northwestern Mutual Investment Management Company LLC lifted its stake in shares of CVS Health by 0.3% in the fourth quarter. Northwestern Mutual Investment Management Company LLC now owns 40,560 shares of the pharmacy operator’s stock valued at $3,219,000 after buying an additional 136 shares during the period. Finally, CoreCap Advisors LLC lifted its position in CVS Health by 4.2% in the second quarter. CoreCap Advisors LLC now owns 3,481 shares of the pharmacy operator’s stock worth $360,000 after purchasing an additional 139 shares during the period. 80.66% of the stock is currently owned by institutional investors.

CVS Health Stock Performance

Shares of NYSE:CVS opened at $93.01 on Friday. The business has a fifty day moving average of $102.02 and a 200-day moving average of $88.86. The company has a debt-to-equity ratio of 0.74, a quick ratio of 0.66 and a current ratio of 0.87. CVS Health Corporation has a twelve month low of $69.51 and a twelve month high of $110.68. The firm has a market cap of $118.96 billion, a PE ratio of 24.61, a price-to-earnings-growth ratio of 0.85 and a beta of 0.61.

CVS Health (NYSE:CVS – Get Free Report) last issued its quarterly earnings data on Wednesday, August 5th. The pharmacy operator reported $2.58 EPS for the quarter, topping analysts’ consensus estimates of $1.87 by $0.71. The firm had revenue of $106.10 billion for the quarter, compared to analyst estimates of $100.03 billion. CVS Health had a net margin of 1.18% and a return on equity of 13.12%. The company’s revenue was up 7.3% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.81 EPS. CVS Health has set its FY 2026 guidance at 7.900-8.100 EPS. On average, equities research analysts predict that CVS Health Corporation will post 8.02 EPS for the current fiscal year.

CVS Health Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Monday, August 3rd. Stockholders of record on Thursday, July 23rd were paid a dividend of $0.665 per share. This represents a $2.66 annualized dividend and a dividend yield of 2.9%. The ex-dividend date of this dividend was Thursday, July 23rd. CVS Health’s dividend payout ratio is 70.37%.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on CVS. DA Davidson increased their price objective on shares of CVS Health from $80.00 to $100.00 and gave the company a “buy” rating in a research note on Thursday, May 7th. JPMorgan Chase & Co. increased their price target on shares of CVS Health from $111.00 to $118.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 12th. UBS Group lifted their price objective on CVS Health from $122.00 to $126.00 and gave the company a “buy” rating in a report on Thursday, August 6th. Wells Fargo & Company upped their price objective on CVS Health from $103.00 to $123.00 and gave the company an “overweight” rating in a research note on Monday, July 13th. Finally, Royal Bank Of Canada raised their target price on CVS Health from $107.00 to $113.00 and gave the stock an “outperform” rating in a research report on Thursday, July 9th. Twenty-two research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat, CVS Health currently has a consensus rating of “Moderate Buy” and a consensus price target of $107.17.

Read Our Latest Research Report on CVS

CVS Health Profile

(Free Report)

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.

Further Reading

Want to see what other hedge funds are holding CVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CVS Health Corporation (NYSE:CVS – Free Report).